Protection of bone marrow progenitor cells by superoxide dismutase.
Intravenously administered cuprozinc-superoxide dismutase in X-irradiated mice hastens the recovery of peripheral blood cells. This effect is consistent with protection of the pluripotent stem cells by the enzyme. Amongst the bone marrow cells committed to differentiation along the myeloid pathway, there exists in mice a subpopulation of macrophage progenitor cells that is inactivated by superoxide radicals, generated photochemically or by X-rays. This cell killing effect is inhibited by superoxide dismutase, in part because it acts intracellularly. Human bone marrow also contain a superoxide-sensitive subpopulation of myeloid progenitor cells that is protected by superoxide dismutase but not by catalase. As well, human myeloid progenitor cells contain a subpopulation with enhanced sensitivity to X-rays in vitro. Treatment of these cells with exogenous superoxide dismutase reduces the sensitivity to X-rays by a factor of 2.
Petkau
A
A
Atomic Energy of Canada Limited Research Company, Whiteshell Nuclear Research Establishment, Pinawa.
D000818:Animals; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects*; D001854:Bone Marrow Cells; D005260:Female; D005609:Free Radicals; D006098:Granulocytes / Q000528:radiation effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D008297:Male; D051379:Mice; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D013045:Species Specificity; D013482:Superoxide Dismutase / Q000627:therapeutic use*
D005609:Free Radicals; D011837:Radiation-Protective Agents; D013482:Superoxide Dismutase